Microchip Technology Analysts Increase Their Forecasts After Better-Than-Expected Q1 Results

Microchip Technology (MCHP) reported robust Q1 fiscal 2026 results, with EPS of $0.27 and sales of $1.075 billion exceeding analyst consensus estimates of $0.23 and $1.054 billion, respectively. The company also issued strong Q2 adjusted EPS guidance of $0.34-$0.37, well above the $0.30 market estimate, alongside a sales outlook of $1.110-$1.150 billion, which encompasses and potentially surpasses expectations. CEO Steve Sanghi highlighted 10.8% sequential revenue growth and successful execution of their recovery plan, signaling a strong emergence from the industry downturn and prompting analysts to raise price targets.

Analysis

Microchip Technology (MCHP) reported a strong start to its fiscal 2026, with first-quarter results surpassing consensus estimates. The company posted quarterly earnings of $0.27 per share against a $0.23 estimate and sales of $1.075 billion, beating the $1.054 billion forecast. This performance was underscored by a 10.8% sequential revenue growth, which management attributed to the successful execution of its nine-point recovery plan. The forward-looking guidance is particularly robust, with the company projecting second-quarter adjusted EPS of $0.34 to $0.37, significantly above the market's $0.30 estimate. The sales forecast of $1.110 billion to $1.150 billion brackets the consensus of $1.115 billion, implying potential for a further beat. According to CEO Steve Sanghi, the company is emerging from the prolonged industry downturn with enhanced operational capabilities and accelerating momentum. This positive outlook has been validated by the market, with analysts at Needham and Piper Sandler reaffirming their Buy/Overweight ratings and raising price targets to $77 and $80, respectively, from previous targets in the mid-$60s.

Key Decisions for Investors

• Given the substantial earnings beat and upwardly revised guidance, the results support a bullish thesis, suggesting the company's recovery is accelerating faster than previously anticipated.
• Investors should note the new analyst price targets of $77-$80, which represent a significant premium to the current trading price, indicating that the market may not have fully priced in the improved outlook.
• Monitor future reports for continued execution on the company's recovery plan and sustained sequential growth, as management has set a clear expectation of capitalizing on the industry recovery.